SKU:  PME-C100016     Target:  SELPLG

Price:10μg $95.00; 50μg $330.00; 100μg $500.00

SKU:  PME-C100082     Target:  FCGR3A

Price: 10μg $72.00 ; 50μg $274.00 ; 100μg $411.00

SKU:  PME-C100015     Target:  IL18BP

Price: 10μg $100.00 ; 50μg $375.00 ; 100 μg $550.00

SKU:  PME-C100013     Target:  CLEC4C

Price: 10μg $100.00 ; 50μg $375.00 ; 100 μg $550.00

SKU:  PME-C100001     Target:  IL18BP

Price: 10μg $100.00 ; 50μg $375.00 ; 100 μg $550.00

SKU:  PME-C100033     Target:  CEACAM5

Price:10μg $120.00; 50μg $380.00; 100μg $570.00

SKU:  PME-C100019     Target:  TNFSF15

Price:10μg $95.00; 50μg $330.00; 100μg $500.00

SKU:  PME-C100078     Target:  SLITRK6

Price: 10μg $100.00 ; 50μg $358.00 ; 100μg $528.00

SKU:  PME-C100050     Target:  CLDN18.2

Price: 10μg $118.00; 50μg $409.00 ; 100 μg $615.00

SKU:  PME-C100045     Target:  NECTIN4

Price: 10μg $118.00; 50μg $429.00 ; 100 μg $645.00

SKU:  PME-C100039     Target:  Mesothelin

Price: 10μg $118.00; 50μg $409.00 ; 100 μg $615.00

SKU:  PME-C100088     Target:  CXCR2

Price:10μg $100.00 ; 50μg $358.00 ; 100μg $528.00

SKU:  PME-C100071     Target:  GPC3

Price: 10μg $120.00 ; 50μg $450.00 ; 100 μg $660.00

SKU:  PME-C100072     Target:  GPC3

Price: 10μg $120.00 ; 50μg $450.00 ; 100 μg $660.00

SKU:  PME-C100068     Target:  MUC1

Price:10μg $81.00 ; 50μg $296.00 ; 100μg $444.00

SKU:  PME-C100026     Target:  MUC1

Price: 10μg $104.00 ; 50μg $386.00 ; 100 μg $570.00

SKU:  PME-C100062     Target:  DLL3

Price: 10μg $82.00; 50μg $320.00 ; 100 μg $480.00

SKU:  PME-C100063     Target:  DLL3

Price: 10μg $82.00; 50μg $320.00 ; 100 μg $480.00

SKU:  PME-C100064     Target:  DLL3

Price: 10μg $82.00; 50μg $320.00 ; 100 μg $480.00

SKU:  PME-C100065     Target:  DLL3

Price: 10μg $82.00; 50μg $320.00 ; 100 μg $480.00


Posts found

CDH17 ADCs blooms in 2025 AACR

The 116th AACR Annual Meeting will be held from April 25 to 30, 2025, at [...]

HER2 | A Key Target in Solid Tumor Therapy

On November 20, 2024, Jazz Pharmaceuticals announced that the bispecific antibody Zanidatamab had received accelerated [...]

PSMA: A Key Target for Radiotherapy and Diagnosis in Prostate Cancer

Prostate-specific membrane antigen (PSMA) is a pivotal molecular target in the treatment and diagnosis of [...]

CD73: A Potential Target in Cancer Immunotherapy

On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and [...]

HER3/ERBB3: Dominating Cancer Therapy with ADCs and Beyond

On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a [...]

Research Progress on BCMA-Targeted Therapies in Multiple Myeloma

On August 27, 2024, Legend Biotech’s BCMA CAR-T product, Carvykti® (generic name: ciltacabtagene autoleucel injection), [...]

Research Progress on Targeting BCMA in Autoimmune Diseases

The B cell maturation antigen (BCMA), a target that gained prominence due to its association [...]

The Fate of ADAM9 ADCs: What Lies Ahead After AbbVie’s Decision?

In March 2024, AbbVie announced its decision to terminate the development of IMGC936 in collaboration [...]

CDH6 ADC: Promising Results for Ovarian Cancer Treatment!

In March 2024, a preclinical study titled “Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a [...]

Nectin-4: A Promising Target in Antibody-Drug Conjugate (ADC) Therapy

During the 2024 ASCO conference, Professor Zhang Jian of Fudan University’s Cancer Hospital unveiled the [...]


Pages found